SG11202006470RA - Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma - Google Patents
Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphomaInfo
- Publication number
- SG11202006470RA SG11202006470RA SG11202006470RA SG11202006470RA SG11202006470RA SG 11202006470R A SG11202006470R A SG 11202006470RA SG 11202006470R A SG11202006470R A SG 11202006470RA SG 11202006470R A SG11202006470R A SG 11202006470RA SG 11202006470R A SG11202006470R A SG 11202006470RA
- Authority
- SG
- Singapore
- Prior art keywords
- pyridin
- fluoro
- methylsulfonimidoyl
- methoxyphenyl
- amine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18156576 | 2018-02-13 | ||
| PCT/EP2019/053407 WO2019158517A1 (en) | 2018-02-13 | 2019-02-12 | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006470RA true SG11202006470RA (en) | 2020-08-28 |
Family
ID=61223765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006470RA SG11202006470RA (en) | 2018-02-13 | 2019-02-12 | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11701347B2 (zh) |
| EP (1) | EP3752487A1 (zh) |
| JP (1) | JP7280286B2 (zh) |
| KR (1) | KR20200119800A (zh) |
| CN (1) | CN111727183B (zh) |
| AU (1) | AU2019221019B2 (zh) |
| BR (1) | BR112020016389A2 (zh) |
| CA (1) | CA3090843A1 (zh) |
| CL (1) | CL2020002087A1 (zh) |
| EA (1) | EA202091894A1 (zh) |
| IL (1) | IL276437B2 (zh) |
| JO (1) | JOP20200196A1 (zh) |
| MA (1) | MA51820A (zh) |
| MX (1) | MX2020008447A (zh) |
| SG (1) | SG11202006470RA (zh) |
| WO (1) | WO2019158517A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018114798A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| BR112020016389A2 (pt) | 2018-02-13 | 2020-12-15 | Bayer Aktiengesellschaft | Uso de 5-fluor-4-(4-fluor-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para tratamento de linfoma difuso de células b grandes |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1307271A (en) | 1970-06-25 | 1973-02-14 | Shell Int Research | Sulphoximine derivatives and their use in herbicidal compositions |
| AU770600B2 (en) | 1999-10-07 | 2004-02-26 | Amgen, Inc. | Triazine kinase inhibitors |
| WO2002059110A1 (en) | 2000-12-21 | 2002-08-01 | Glaxo Group Limited | Pyrimidineamines as angiogenesis modulators |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| WO2003037346A1 (en) | 2001-10-31 | 2003-05-08 | Cell Therapeutics, Inc. | 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer |
| SI2256108T1 (sl) | 2002-07-18 | 2016-05-31 | Janssen Pharmaceutica N.V. | Substituirani triazinski kinazni inhibitorji |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| AU2004212421B2 (en) | 2003-02-07 | 2009-08-20 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
| US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| AU2005291117B2 (en) | 2004-10-05 | 2011-06-09 | Syngenta Limited | Isoxazoline derivatives and their use as herbicides |
| EP1828183A1 (en) | 2004-12-17 | 2007-09-05 | AstraZeneca AB | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
| DE102005062742A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
| EP1803723A1 (de) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
| JP4305477B2 (ja) | 2006-07-25 | 2009-07-29 | トヨタ自動車株式会社 | 火花点火式内燃機関 |
| DE102006041382A1 (de) | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
| DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
| WO2008060248A1 (en) | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| US20100093776A1 (en) | 2006-12-22 | 2010-04-15 | Novartis Ag | Organic Compounds and Their Uses |
| US20100048597A1 (en) | 2006-12-22 | 2010-02-25 | Novartis Ag | Organic Compounds and Their Uses |
| KR20150043565A (ko) | 2007-03-12 | 2015-04-22 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2008129071A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| US8436007B2 (en) | 2007-04-24 | 2013-05-07 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| US8507498B2 (en) | 2007-04-24 | 2013-08-13 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
| EP2200436B1 (en) | 2007-09-04 | 2015-01-21 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| US8124764B2 (en) | 2008-07-14 | 2012-02-28 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitor compounds |
| US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| AU2010291212A1 (en) | 2009-09-04 | 2012-02-23 | Novartis Ag | Heteroaryl compounds as kinase inhibitors |
| TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
| BR112012008677A2 (pt) | 2009-10-12 | 2018-03-20 | Myrexis Inc | compostos amino-pirimidina como inibidores de tbkl e/ou ikk epsilon |
| CN102933561B (zh) | 2010-03-22 | 2016-05-11 | 利德发现中心有限责任公司 | 具有药学活性的二取代三嗪衍生物 |
| DE102010046720A1 (de) | 2010-09-23 | 2012-03-29 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| EA201390717A1 (ru) | 2010-11-17 | 2013-10-30 | Новартис Аг | 3-(аминоарил)пиридиновые соединения |
| WO2012101065A2 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Pyrimidine biaryl amine compounds and their uses |
| WO2012101066A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Pyridine biaryl amine compounds and their uses |
| WO2012101064A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| WO2012101063A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
| CN103339110A (zh) | 2011-01-28 | 2013-10-02 | 诺瓦提斯公司 | 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途 |
| WO2012117048A1 (en) | 2011-03-02 | 2012-09-07 | Lead Discovery Center Gmbh | Pharmaceutically active disubstituted triazine derivatives |
| US9242937B2 (en) | 2011-03-02 | 2016-01-26 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted pyridine derivatives |
| CA2832919A1 (en) | 2011-04-12 | 2012-10-18 | Ryan C. Holcomb | Compounds, compositions, and therapeutic uses thereof |
| CN102731413A (zh) | 2011-04-15 | 2012-10-17 | 上海医药工业研究院 | 一种脲类化合物、其制备方法、其中间体及其应用 |
| MX2013012233A (es) | 2011-04-19 | 2014-01-23 | Bayer Pharma AG | 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas. |
| EP2527332A1 (en) | 2011-05-24 | 2012-11-28 | Bayer Intellectual Property GmbH | 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors |
| TW201636330A (zh) | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| CA2848616A1 (en) | 2011-09-16 | 2013-03-21 | Bayer Intellectual Property Gmbh | Disubstituted 5-fluoro-pyrimidines |
| EP2755948B1 (en) | 2011-09-16 | 2016-05-25 | Bayer Intellectual Property GmbH | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group |
| CA2888381A1 (en) | 2012-10-18 | 2014-04-24 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group |
| AP3872A (en) | 2012-11-15 | 2016-10-31 | Bayer Pharma AG | 5-Fluoro-n-(pyridin-2-yl) pyridin-2-amine derivatives containing a sulfoximine group |
| EP2920153B1 (en) | 2012-11-15 | 2017-02-01 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group |
| US9770445B2 (en) | 2013-07-04 | 2017-09-26 | Bayer Pharma Aktiengesellschaft | Sulfoximine substituted 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives and their use as CDK9 kinase inhibitors |
| US9856242B2 (en) | 2014-03-13 | 2018-01-02 | Bayer Pharma Aktiengesellscaft | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
| CN107427520A (zh) | 2015-03-24 | 2017-12-01 | 拜耳医药股份有限公司 | 4‑(4‑氟‑2‑甲氧基苯基)‑n‑{3‑[(s‑甲基磺酰亚氨基)甲基]苯基}‑1，3，5‑三嗪‑2‑胺用于治疗淋巴瘤的用途 |
| BR112020016389A2 (pt) | 2018-02-13 | 2020-12-15 | Bayer Aktiengesellschaft | Uso de 5-fluor-4-(4-fluor-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para tratamento de linfoma difuso de células b grandes |
-
2019
- 2019-02-12 BR BR112020016389-9A patent/BR112020016389A2/pt not_active Application Discontinuation
- 2019-02-12 EA EA202091894A patent/EA202091894A1/ru unknown
- 2019-02-12 MX MX2020008447A patent/MX2020008447A/es unknown
- 2019-02-12 MA MA051820A patent/MA51820A/fr unknown
- 2019-02-12 JP JP2020565543A patent/JP7280286B2/ja active Active
- 2019-02-12 AU AU2019221019A patent/AU2019221019B2/en active Active
- 2019-02-12 US US16/969,460 patent/US11701347B2/en active Active
- 2019-02-12 IL IL276437A patent/IL276437B2/en unknown
- 2019-02-12 EP EP19704618.8A patent/EP3752487A1/en active Pending
- 2019-02-12 JO JOP/2020/0196A patent/JOP20200196A1/ar unknown
- 2019-02-12 WO PCT/EP2019/053407 patent/WO2019158517A1/en unknown
- 2019-02-12 SG SG11202006470RA patent/SG11202006470RA/en unknown
- 2019-02-12 KR KR1020207022928A patent/KR20200119800A/ko not_active Application Discontinuation
- 2019-02-12 CA CA3090843A patent/CA3090843A1/en active Pending
- 2019-02-12 CN CN201980013294.2A patent/CN111727183B/zh active Active
-
2020
- 2020-08-12 CL CL2020002087A patent/CL2020002087A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020008447A (es) | 2020-09-28 |
| JOP20200196A1 (ar) | 2020-08-13 |
| JP7280286B2 (ja) | 2023-05-23 |
| US20210015806A1 (en) | 2021-01-21 |
| WO2019158517A1 (en) | 2019-08-22 |
| IL276437B2 (en) | 2024-03-01 |
| IL276437A (en) | 2020-09-30 |
| BR112020016389A2 (pt) | 2020-12-15 |
| KR20200119800A (ko) | 2020-10-20 |
| CA3090843A1 (en) | 2019-08-22 |
| MA51820A (fr) | 2021-05-19 |
| IL276437B1 (en) | 2023-11-01 |
| JP2021514386A (ja) | 2021-06-10 |
| EA202091894A1 (ru) | 2020-12-28 |
| US11701347B2 (en) | 2023-07-18 |
| CN111727183B (zh) | 2023-12-29 |
| CN111727183A (zh) | 2020-09-29 |
| EP3752487A1 (en) | 2020-12-23 |
| CL2020002087A1 (es) | 2020-12-11 |
| AU2019221019B2 (en) | 2024-05-02 |
| AU2019221019A1 (en) | 2020-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281597A (en) | RNAi agents for suppressing the expression of 17 beta-HSD type 13, (HASD17B13) their preparations and their uses | |
| SG11202001503SA (en) | Axisymmetric adjustable device for treating mitral regurgitation | |
| IL287145A (en) | Methods for treating non-Hondkin's lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1 , 3-dione | |
| IL276437A (en) | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for the treatment of diffuse large B-cell lymphoma | |
| PT3805233T (pt) | Enantiómeros (r) e (s) de n-(5-(3-hidroxipirrolidin-1-il)-2 morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)oxazole-carboxamida como inibidores de irak4 para o tratamento de cancro | |
| IL280123A (en) | Compounds and Methods for Reducing ATXN2 Expression | |
| IL282006B1 (en) | Treatment of bone tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | |
| IL274394A (en) | Compounds and Methods for Reducing SNCA Expression | |
| EP3122360A4 (en) | Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma | |
| SG11202009171XA (en) | Surface treatment method of wafer and composition used for said method | |
| ZA202204809B (en) | 5-ht2a agonists for use in treatment of depression | |
| DK3490625T3 (da) | Indretning med struktureret belægning til brug som implantat til behandling af perforeringer i trommehinden | |
| HUE060654T2 (hu) | Heterokondelzált piridonvegyületek és azok IDH-gátlóként történõ alkalmazása | |
| IL280721A (en) | A method for treating relapse of follicular lymphoma | |
| SG11202108625WA (en) | Compounds and methods for reducing kcnt1 expression | |
| SG11202008895WA (en) | Modified oligonucleotides for use in treatment of tauopathies | |
| IL273909A (en) | Treatment of CD20-positive B-cell lymphoma with obituzumab | |
| IL288900A (en) | Treatment including fxr agonists | |
| IL283054A (en) | Methods for treating myelodysplastic syndrome | |
| DK4036095T3 (da) | 4-fluor-1h-pyrazolo[3,4-c]pyridinderivater som selektive bruton-tyrosinkinase- (btk) inhibitorer til behandlingen af b-cellelymfom og autoimmunsygdomme | |
| IL275384A (en) | Methods and compositions for pre-emptive treatment of graft versus host disease | |
| IL278904A (en) | Compounds for the treatment of pain, preparations containing them and methods of using them | |
| EP3873498A4 (en) | METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CARCINOMA USING ANTISENSE NUCLEIC ACIDS | |
| MX2020005557A (es) | Agonistas de fxr para el tratamiento de enfermedades hepaticas. | |
| IL276576A (en) | Therapeutic factors for the treatment of restless legs syndrome |